Unicycive Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.607; its P/E ratio is -0.67; Unicycive Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.15. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	-	-	$ 675.00K	-
Gross Profit	-	-	-	$ 675.00K	-
EBIT	$ -18.15M	$ -4.32M	$ -3.81M	$ 5.55M	$ -5.33M
EBITDA	$ -18.07M	$ -4.24M	$ -3.73M	$ 5.60M	$ -5.28M
Net Income Common Stockholders	$ -7.80M	$ -4.41M	$ -4.44M	$ 5.36M	$ -5.33M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 9.70M	$ 14.35M	$ 18.82M	$ 24.33M	$ 455.00K
Total Assets	$ 14.19M	$ 19.44M	$ 22.88M	$ 27.18M	$ 2.82M
Total Debt	$ 793.00K	$ 866.00K	$ 937.00K	$ 991.00K	$ 155.00K
Net Debt	$ -8.91M	$ -13.48M	$ -17.88M	$ -23.34M	$ -300.00K
Total Liabilities	$ 18.00M	$ 16.01M	$ 42.26M	$ 16.68M	$ 3.28M
Stockholders Equity	$ -3.81M	$ 3.39M	$ -19.37M	$ 10.52M	$ -466.00K
Cash Flow	-
Free Cash Flow	$ -4.44M	$ -4.42M	$ -5.57M	$ -3.87M	$ -6.08M
Operating Cash Flow	$ -4.44M	$ -4.42M	$ -5.56M	$ -3.87M	$ -6.08M
Investing Cash Flow	-	-	$ -12.00K	-	-
Financing Cash Flow	$ -205.00K	$ -51.00K	-	$ 27.80M	$ -471.00K

Currency in USD

Unicycive Therapeutics Earnings and Revenue History

Income Statement >

Unicycive Therapeutics Debt to Assets

Balance Sheet >

Unicycive Therapeutics Cash Flow

Cash Flow >

Unicycive Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing